Biogen walks away from controversial Alzheimer’s drug Aduhelm
[ Drugmaker Biogen said Wednesday it will give up its ownership of Aduhelm, the Alzheimer’s treatment drug that sparked intense criticism of the company and the Food and Drug Administration (FDA) after it was approved in 2021. The company will also terminate an ongoing post-approval clinical trial that the FDA ordered to confirm the … Read more
